CD274 and neoplasm: These results suggest a promising adjuvant strategy for the treatment of TNBC by enhancing the expression of PD–L1 in the tumors and reversing the immune suppressive tumor microenvironment to overcome the αPD–L1–irresponsiveness of TNBC.